Mark A. Velleca, Director at G1 Therapeutics, Inc. (GTHX), sold 50,000 shares at $18.49 ($946K) on 2021-07-15, disclosed to the SEC on 2021-07-15.
Open-market sale of $946k GTHX by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.45 | 10,000 | $195K | 20.6% |
| 2 | $19.08 | 10,000 | $191K | 20.2% |
| 3 | $19.08 | 10,000 | $191K | 20.2% |
| 4 | $18.49 | 10,000 | $185K | 19.5% |
| 5 | $18.49 | 10,000 | $185K | 19.5% |
| Total | $18.92 avg | 50,000 |
| $946K |
| 100% |
| Filing → |
| GTHX | SELL | 2022-09-22 | $270K | — | Filing → |
| GTHX | SELL | 2022-08-18 | $1.0M | — | Filing → |
| GTHX | SELL | 2021-06-17 | $876K | — | Filing → |